R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways

Molecular Cancer Therapeutics

Volumn 3, Issue 2, 2004, Pages 179-186

  Beaupre, Darrin M ^a,b   Cepero, Enrique ^a   Obeng, Esther A ^a   Boise, Lawrence H ^a,b   Lichtenheld, Mathias G ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CASPASE 9; INTERLEUKIN 6 RECEPTOR; PROTEIN BAX; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; TIPIFARNIB;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MECHANISM; DRUG SENSITIVITY; ENDOPLASMIC RETICULUM; GENE MUTATION; GENE OVEREXPRESSION; MITOCHONDRIAL MEMBRANE; MULTIPLE MYELOMA; MYELOMA CELL; PRENYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; STRESS;

APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CASPASE 9; CASPASES; CCAAT-ENHANCER-BINDING PROTEINS; CELL DIVISION; CELL LINE, TUMOR; HUMANS; INTRACELLULAR MEMBRANES; MEMBRANE POTENTIALS; MEMBRANE PROTEINS; MITOCHONDRIA; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PROTEIN ISOPRENYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; QUINOLONES; RAS PROTEINS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROPEPTIDE; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR CHOP; TRANSCRIPTION FACTORS;

EID: 4444314787     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Kalakonda N, Rothwell DG, Scarffe JH, Norton JD. Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation. Blood, 2001;98:1555-60.
2. Bezieau S, Devilder MC, Avet-Loiseau H, Mellerin MP, Puthier D, Pennarun E, et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat, 2001;18:212-24.
3. Ogata A, Chauhan D, Teoh G, Treon SP, Urashima M, Schlossman RL, et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol, 1997;159:2212-21.
4. Downward J. Ras signalling and apoptosis. Curr Opin Genet Dev, 1998;8:49-54.
5. Beaupre DM, McCafferty-Grad J, Bahlis NJ, Boise LH, Lichtenheld MG. Farnesyl transferase inhibitors enhance death receptor signals and induce apoptosis in multiple myeloma cells. Leuk Lymphoma, 2003;44: 2123-34.
6. Le Gouill S, Pellat-Deceunynck C, Harousseau JL, Rapp MJ, Robillard N, Bataille R, et al. Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells. Leukemia, 2002;16:1664-7.
7. Bolick SC, Landowski TH, Boulware D, Oshiro MM, Ohkanda J, Hamilton AD, et al. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells. Leukemia, 2003;17:451-7.
8. Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Price-Troska T, et al. The farnesyltransferase inhibitor Zarnestra is well tolerated, induces stabilization of disease and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood, 2004; in press.
9. Grad JM, Bahlis NJ, Reis I, Oshiro MM, Dalton WS, Boise LH. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood, 2001;98:805-13.
10. Khaled AR, Kim K, Hofmeister R, Muegge K, Durum SK. Withdrawal of IL-7 induces Bax translocation from cytosol to mitochondria through a rise in intracellular pH. Proc Natl Acad Sci USA, 1999;96:14476-81.
11. Bellosillo B, Villamor N, Lopez-Guillermo A, Marce S, Bosch F, Campo E, et al. Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia. Blood, 2002;100:1810-6.
12. Hengartner MO. The biochemistry of apoptosis. Nature, 2000;407: 770-6.
13. Morishima N, Nakanishi K, Takenouchi H, Shibata T, Yasuhiko Y. An endoplasmic reticulum stress-specific caspase cascade in apoptosis. Cytochrome c-independent activation of caspase-9 by caspase-12. J Biol Chem, 2002;277:34287-94.
14. Harada N, Hata H, Yoshida M, Soniki T, Nagasaki A, Kuribayashi N, et al. Expression of Bcl-2 family of proteins in fresh myeloma cells. Leukemia, 1998;12:1817-20.
15. Miguel-Garcia A, Orero T, Matutes E, Carbonell F, Miguel-Sosa A, Linares M, et al. bcl-2 expression in plasma cells from neoplastic gammopathies and reactive plasmacytosis: a comparative study. Haematologica, 1998;83:298-304.
16. Pettersson M, Jernberg-Wiklund H, Larsson LG, Sundstrom C, Givol I, Tsujimoto Y, et al. Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. Blood, 1992;79:495-502.
17. Egle A, Villunger A, Marschitz I, Kos M, Hittmair A, Lukas P, et al. Expression of Apo-1/Fas (CD95), Bcl-2, Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status. Br J Haematol, 1997;97:418-28.
18. Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood, 2002;99:1885-93.
19. Zhang B, Potyagaylo V, Fenton RG. IL-6-independent expression of Mcl-1 in human multiple myeloma. Oncogene, 2003;22:1848-59.
20. Spets H, Stromberg T, Georgii-Hemming P, Siljason J, Nilsson K, Jernberg-Wiklund H. Expression of the bcl-2 family of pro- and anti-apoptotic genes in multiple myeloma and normal plasma cells: regulation during interleukin-6 (IL-6)-induced growth and survival. Eur J Haematol, 2002;69:76-89.
21. Wei MC, Zong WX, Chang EH, Lindsen T, Panoutsakopoulou V, Ross AJ, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science, 2001;292:727-30.
22. Suzuki N, Urano J, Tamanoi F. Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. Proc Natl Acad Sci USA, 1998;95:15356-61.
23. Hsu YT, Wolter KG, Youle RJ. Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. Proc Natl Acad Sci USA, 1997;94: 3668-72.
24. Kaufman RJ. Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes Dev, 1999;13:1211-33.
25. Lee AS. The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem Sci, 2001;26:504-10.
26. Wang XZ, Lawson B, Brewer JW, Zinszner H, Sanjay A, Mi LJ, et al. Signals from the stressed endoplasmic reticulum induce C/EBP-homologous protein (CHOP/GADD153). Mol Cell Biol, 1996;16:4273-80.
27. Neri A, Murphy JP, Cro L, Ferrero D, Tarella C, Baldini L, et al. Ras oncogene mutation in multiple myeloma. J Exp Med, 1989;170: 1715-25.
28. Liu P, Leong T, Quam L, Billadeau D, Kay NE, Greipp P, et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood, 1996;88:2699-706.
29. Portier M, Moles JP, Mazars GR, Jeanteur P, Bataille R, Klein B, et al. p53 and RAS gene mutations in multiple myeloma. Oncogene, 1992;7: 2539-43.
30. Shi Y, Gera J, Hsu JH, Van Ness B, Lichtenstein A. Cytoreductive effects of farnesyl transferase inhibitors on multiple myeloma tumor cells. Mol Cancer Ther, 2003;2:563-72.
31. End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res, 2001;61:131-7.
32. Whyte DB, Kirschmeier P, Hockenberry TIN, Nunez-Oliva I, James L, Catino JJ, et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem, 1997;272: 14459-64.
33. Zhang FL, Kirschmeier P, Carr D, James L, Bond RW, Wang L, et al. Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I. J Biol Chem, 1997;272:10232-9.
34. Ferri KF, Kroemer G. Organelle-specific initiation of cell death pathways. Nat Cell Biol, 2001;3:E255-63.
35. Nakagawa T, Zhu H, Morishima N, Li E, Xu J, Yankner BA, et al. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-β. Nature, 2000;403:98-103.
36. Gajkowska B, Motyl T, Olszewska-Badarczuk H, Godlewski MM. Expression of BAX in cell nucleus after experimentally induced apoptosis revealed by immunogold and embedment-free electron microscopy. Cell Biol Int, 2001;25:725-33.
37. Godlewski MM, Motyl MA, Gajkowska B, Wareski P, Koronkiewicz M, Motyl T. Subcellular redistribution of BAX during apoptosis induced by anticancer drugs. Anticancer Drugs, 2001;12:607-17.
38. Nutt LK, Pataer A, Pahler J, Fang B, Roth J, McConkey DJ, et al. Bax and Bak promote apoptosis by modulating endoplasmic reticular and mitochondrial Ca2+ stores. J Biol Chem, 2002;277:9219-25.
39. Pan Z, Bhat MB, Nieminen AL, Ma J. Synergistic movements of Ca(2+) and Bax in cells undergoing apoptosis. J Biol Chem, 2001;276: 32257-63.
40. Ferrari D, Pinton P, Szabadkai G, Chami M, Campanella M, Pozzan T, et al. Endoplasmic reticulum, Bcl-2 and Ca(2+) handling in apoptosis. Cell Calcium, 2002;32:413-20.
41. Nakagawa T, Yuan J. Cross-talk between two cysteme protease families. Activation of caspase-12 by calpain in apoptosis. J Cell Biol, 2000;150:887-94.
42. Paroni G, Henderson C, Schneider C, Brancolini C. Caspase-2 can trigger cytochrome C release and apoptosis from the nucleus. J Biol Chem, 2002;277:15147-61.
43. Paroni G, Henderson C, Schneider C, Brancolini C. Caspase-2-incluced apoptosis is dependent on caspase-9, but its processing during UV- or tumor necrosis factor-dependent cell death requires caspase-3. J Biol Chem, 2001;276:21907-15.
44. Robertson JD, Enoksson M, Suomela M, Zhivotovsky B, Orrenius S. Caspase-2 acts upstream of mitochondria to promote cytochrome c release during etoposide-induced apoptosis. J Biol Chem, 2002;277: 29803-9.
45. Robertson JD, Gogvadze V, Zhivotovsky B, Orrenius S. Distinct pathways for stimulation of cytochrome c release by etoposide. J Biol Chem, 2000;275:32438-43.
46. Lassus P, Opitz-Araya X, Lazebnik Y. Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science, 2002;297:1352-4.
47. Cox AD, Der CJ. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim Biophys Acta, 1997;1333:F51-71.
48. Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood, 2001;97:3361-9.
49. Cortes J, Albitar M, Thomas D, Giles F, Kurzrock R, Thibault A, et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood, 2003; 101:1692-7.
50. Keating A. Chronic myeloid leukemia: current therapies and the potential role of farnesyltransferase inhibitors. Semin Hematol, 2002;39: 11-7.
51. Kurzrock R, Cortes J, Kantarjian H. Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome. Semin Hematol, 2002;39:20-4.